Medicxi Ventures

In 2016 was created Medicxi Ventures, which is appeared as VC. The fund was located in Europe if to be more exact in United Kingdom. The leading representative office of defined VC is situated in the London.

Among the various public portfolio startups of the fund, we may underline SutroVax, Diasome, Aura Biosciences Among the most successful fund investment fields, there are Biopharma, Genetics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low.

The fund was created by David Grainger, Francesco Rubertis, Giuseppe Zocco, Kevin Johnson, Michele Ollier. The overall number of key employees were 11.

The usual things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 54 percentage points more often commits exit comparing to other organizations. The higher amount of exits for fund were in 2018. The fund is constantly included in 2-6 investment rounds annually. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. Opposing the other organizations, this Medicxi Ventures works on 20 percentage points less the average amount of lead investments.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Medicxi Ventures, startups are often financed by Ysios Capital, Roche Venture Fund, Longitude Capital. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, University of Cambridge Enterprise, OUP (Osage University Partners). In the next rounds fund is usually obtained by Silicon Valley Bank, Oberland Capital, Kite Pharma.

Notable deals

Review

• No reviews are submitted yet.